某医院2011-2014年临床分离革兰阴性杆菌分布及耐药性分析

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (797 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the distribution and drug resistance of main gram-negative bacilli causing nosocomial infections in a certain hospital, so as to provide scientific basis for the infection control and reasonable use of antibiotics in clinics. Methods The main strains were collected from patients’ specimens in this hospital from 2011-2014 .The bacterial identification and drug susceptibility tests were performed and their drug resistance was retrospectively analyzed. Results A total of 12437 gram-negative isolates were collected from non- repetitive clinical specimens during the past four years,of which Enterobacteriaceae and non-fermentative Gram- negative bacilli accounted for 6243(50.2%) and 5920(47.6%), respectively. The Acinetobacter,Pseudomonas aeruginosa,Klebsiella pneumoniae,Escherichia coli were the predominant species of Gram-negative bacilli,accounted for 21.1%,19.4%,16.8% and 8.5% respectively. The source of pathogenic bacteria specimens were mainly from respiratory tract and followed by urinary tract. Infection with high-risk departments were the brain injury rehabilitation department and ICU. By monitoring multi-drug resistant bacteria during four consecutive years,it was found that ESBLs-producing Escherichia coli and Klebsiella pneumoniae(64.9%,64.3%,62.1%,55.4%),(50.1%,47.7%,43.4%,45.7%) showed a trend of decline.But carbapenem- resistant Escherichia coli and Klebsiella pneumoniae(0.8%,1.5%,1.3%,2.6%),(17.4%,30.8%,27.1%,34.1%) had a rising trend year by year. During the past four years, the average detection rate of extensively drug-resistant Acinetobacter was 40.3%. Conclusions Most clinical isolates are Gram-negative bacilli and multi-drug resistant strains increase obviously.The reasonable clinical use of antibiotics is crucial for delay of emergence of drug-resistant strains. It is also necessary to strengthen the surveillance of drug resistance of the pathogens and prevent the spread of MDRO causing nosocomial infection.

Key words： bacterial resistance surveillance Gram-negative bacilli multi-drug resistant bacteria drug susceptibility testing carbapenemase

Received: 09 April 2015

ZTFLH:	R453.2
	R37

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Yonggao
	CHEN Ranfeng
	SUN Long

Cite this article:

HUANG Yonggao,CHEN Ranfeng,SUN Long. Analysis of distribution and drug resistance of gram-negative bacilli causing nosocomial infections from 2011 to 2014 in a hospital[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(7): 702-706.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I7/702

[13]	Lee N Y, Wang C L, Chuang Y C, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study[J]. Pharmacotherapy, 2007,27:1506-1511.
[1]	叶应妩,王毓三,申子瑜.全国临床检验操作规程[M].3版.南京: 东南大学出版社,2006: 715-920.
[14]	Kiffer C R,Sampaio J L, Sinto S,et al.In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J].Diagn Microbiol Infect Dis, 2005, 52:317-322.
[2]	胡付品,朱德妹,汪复,等.2013年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2014,14(5):369-378.
[15]	Petersen P J, Labthavikul P, Jones C H, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis[J]. J Antimicrob Chemother, 2006, 57:573-576.
[3]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twenty-forth informational supplement,2014,M100-S24 Vol 34 No.1.
[4]	汪复,朱德妹,胡付品,等.2012年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2013,13(5): 321-330.
[5]	胡付品,朱德妹,汪复,等.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5): 321-329.
[6]	马艳芳.ICU气管切开患者肺部感染的危险因素分析及干预对策[J].中华医院感染学杂志,2013,23(12): 2808-2813.
[7]	张秀英,陈禄芝,杨再良,等.脑出血患者肺部感染的危险因素分析[J].中华医院感染学杂志,2014,24(6): 1416-1417.
[8]	周华,李光辉,陈佰义,等.中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J].中华医学杂志, 2014, 94(24):1847-1856.
[9]	孙龙,武建.肺炎克雷伯菌医院感染的临床分布及耐药研究[J].实验与检验医学,2012,30(5):478-481.
[10]	Zhang R,Zhou H W,Cai J C,et al.Plasmid-mediated carbapenem-hydrolysing beta-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou, China[J]. J Antimicrob Chemother, 2007, 59(3):574-576.
[11]	Wei Z Q, Du X X, Yu Y S, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China[J]. Antimicrob Agents Chemother, 2007, 51(2): 763-765.
[12]	Cai J C, Zhou H W, Zhang R, et al. Emergence of Serratia marcescens, Klebsiella pneumoniae,and Escherichia coli Isolates possessing the plasmid-mediated carbapenemhydrolyzing beta- lactamase KPC-2 in intensive care units of a Chinese hospital[J]. Antimicrob Agents Chemother, 2008,52(6):2014-2018.
[13]	Lee N Y, Wang C L, Chuang Y C, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study[J]. Pharmacotherapy, 2007,27:1506-1511.
[14]	Kiffer C R,Sampaio J L, Sinto S,et al.In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J].Diagn Microbiol Infect Dis, 2005, 52:317-322.
[15]	Petersen P J, Labthavikul P, Jones C H, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis[J]. J Antimicrob Chemother, 2006, 57:573-576.